GBM
MCID: GLB002
MIFTS: 67

Glioblastoma (GBM)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Glioblastoma

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 11 19 58 75 28 53 5 43 14 71
Glioblastoma Multiforme 11 19 58 75 28 53 5 14 16 71
Gbm 11 58
Grade Iv Adult Astrocytic Tumor 11
Primary Glioblastoma Multiforme 11
Adult Glioblastoma Multiforme 11
Spongioblastoma Multiforme 11
Primary Glioblastoma 71
Adult Glioblastoma 71

Characteristics:


Inheritance:

Multigenic/multifactorial 58

Prevelance:

1-9/100000 58

Age Of Onset:

All ages 58

Age Of Death:

adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3068
MeSH 43 D005909
SNOMED-CT 68 63634009
MESH via Orphanet 44 D005909
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0017636 C1621958
Orphanet 58 ORPHA360
UMLS 71 C0017636 C0278878 C1514422 more

Summaries for Glioblastoma

GARD: 19 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome.

MalaCards based summary: Glioblastoma, also known as glioblastoma multiforme, is related to brain cancer and glioma, and has symptoms including headache and seizures. An important gene associated with Glioblastoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is miRNAs involved in DNA damage response. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and eye, and related phenotypes are glioblastoma multiforme and abnormal cell morphology

Disease Ontology: 11 A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Orphanet: 58 Glioblastomas are malignant astrocytic tumors (grade IV according to the WHO classification).

Wikipedia: 75 Glioblastoma, previously known as glioblastoma multiforme (GBM), is one of the most aggressive types of... more...

Related Diseases for Glioblastoma

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1269)
# Related Disease Score Top Affiliating Genes
1 brain cancer 33.1 MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
2 glioma 32.7 TP73-AS1 MIR34A MIR296 MIR222 MIR221 MIR21
3 high grade glioma 32.6 MIR221 MIR21 MALAT1 HOTAIRM1 HOTAIR GAS5
4 central nervous system cancer 32.1 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
5 neuroblastoma 31.7 MIR34A MIR221 MIR21 MALAT1 HOTAIR GAS5
6 malignant astrocytoma 31.7 MIR34A MIR296 MIR222 MIR221 MIR21 AGAP2-AS1
7 medulloblastoma 31.6 MSH2 MIR34A MIR326 MIR221 MIR182 MIR17HG
8 melanoma 31.5 MIR34A MIR222 MIR221 MIR21 MIR182 MIR137
9 b-cell lymphoma 31.5 MIR17HG MALAT1 HOTAIR GAS5
10 lung cancer 31.4 TP73-AS1 NOS2 MSH2 MIR451A MIR34A MIR296
11 hematologic cancer 31.4 MSH2 MIR34A MIR222 MIR221 MIR21
12 hepatocellular carcinoma 31.3 TP73-AS1 NOS2 MSH2 MIR34A MIR222 MIR221
13 leukemia, acute lymphoblastic 31.3 MSH2 MIR451A MIR222 MIR221 MIR21
14 leukemia, acute myeloid 31.3 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
15 colorectal cancer 31.2 NOS2 MSH2 MIR451A MIR34A MIR296 MIR222
16 breast cancer 31.2 TP73-AS1 NOS2 MSH2 MIR451A MIR34A MIR222
17 lung cancer susceptibility 3 31.2 MIR296 MIR21 MIR182 MALAT1 HOTAIR GAS5
18 kidney cancer 31.1 MIR221 MIR21 MIR182 MALAT1 HOTAIR GAS5
19 central nervous system disease 31.1 MIR34A MIR222 MIR221 MIR21
20 ovarian cancer 31.1 MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
21 prostate cancer 31.1 MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
22 renal cell carcinoma, nonpapillary 31.0 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
23 small cell cancer of the lung 31.0 MIR21 MALAT1 HOTAIR
24 bladder cancer 31.0 MSH2 MIR222 MIR221 MIR21 MALAT1 HOTAIR
25 diffuse large b-cell lymphoma 31.0 MIR222 MIR221 MIR21 MIR17HG HOTAIR
26 head and neck cancer 31.0 MIR34A MIR296 MIR222 MIR221 MIR21 GAS5
27 cellular ependymoma 31.0 MSH2 HOTAIR
28 esophageal cancer 31.0 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
29 retinitis pigmentosa 11 30.9 MIR296 MIR182 HOTAIRM1 HOTAIR GAS5
30 pancreatic cancer 30.9 MSH2 MIR34A MIR222 MIR221 MIR21 MALAT1
31 thyroid carcinoma 30.8 MALAT1 HOTAIR GAS5
32 cervical cancer 30.8 MIR34A MIR221 MIR21 MALAT1 HOTAIR GAS5
33 hypertension, essential 30.8 NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
34 myeloma, multiple 30.8 TP73-AS1 MIR221 MIR21 MALAT1 HOTAIR GAS5
35 leukemia, chronic lymphocytic 30.7 MIR34A MIR221 MIR21 MIR182 MIR17HG
36 spinal disease 30.6 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
37 esophagus squamous cell carcinoma 30.6 TP73-AS1 MIR296 MALAT1 HOTAIR GAS5
38 gastric cancer 30.6 MSH2 MIR451A MIR34A MIR222 MIR221 MIR21
39 thyroid cancer, nonmedullary, 1 30.6 MIR222 MIR221 MALAT1 HOTAIR
40 rectum cancer 30.6 MSH2 MIR221 MIR21
41 muscular dystrophy, duchenne type 30.6 MIR34A MIR222 MIR221 MIR21
42 nervous system disease 30.5 NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
43 bone disease 30.5 MIR34A MIR222 MIR221 MIR21
44 nasopharyngeal carcinoma 30.4 MIR296 MIR21 MALAT1 HOTAIR GAS5
45 pancreatic ductal adenocarcinoma 30.4 MIR34A MIR222 MIR221 MIR21 MALAT1 HOTAIRM1
46 thoracic cancer 30.4 MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
47 lymphatic system disease 30.4 MIR34A MIR222 MIR221 MIR21 MIR182
48 ovarian epithelial cancer 30.1 MALAT1 HOTAIR
49 mantle cell lymphoma 29.7 MIR17HG MALAT1 GAS5
50 glioma susceptibility 1 11.8

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma

Symptoms & Phenotypes for Glioblastoma

Human phenotypes related to Glioblastoma:

30 58 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glioblastoma multiforme 30 Obligate (100%) HP:0012174
2 abnormal cell morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0025461
3 muscle weakness 58 30 Frequent (33%) Frequent (79-30%)
HP:0001324
4 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
5 headache 58 30 Frequent (33%) Frequent (79-30%)
HP:0002315
6 visual loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0000572
7 abnormal corpus callosum morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0001273
8 language impairment 58 30 Frequent (33%) Frequent (79-30%)
HP:0002463
9 paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0003470
10 cerebral edema 58 30 Frequent (33%) Frequent (79-30%)
HP:0002181
11 emotional lability 30 Frequent (33%) HP:0000712
12 memory impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002354
13 seizure 30 Occasional (7.5%) HP:0001250
14 seizures 58 Occasional (29-5%)
15 abnormality of the cerebral white matter 58 Frequent (79-30%)
16 abnormality of nervous system physiology 58 Frequent (79-30%)
17 mood changes 58 Frequent (79-30%)
18 glioblastoma 58 Obligate (100%)

UMLS symptoms related to Glioblastoma:


headache; seizures

Drugs & Therapeutics for Glioblastoma

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 523)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
5
Citalopram Approved Phase 2, Phase 3 59729-32-7, 59729-33-8 2771
6
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Hydroxyurea Approved Phase 3 127-07-1 3657
9
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
10
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
11
Tofacitinib Approved, Investigational Phase 3 477600-75-2 9926791
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
14
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
15
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
16
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
17
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
18
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
19
Duloxetine Approved Phase 3 136434-34-9, 116539-59-4 60835
20
Norepinephrine Approved Phase 3 51-41-2 439260
21
Ascorbic acid Approved, Nutraceutical Phase 3 50-81-7 54676860 54670067 5785
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 2052-63-3, 22737-97-9, 22737-96-8, 68-26-8 9904001 9947823 5280382 445354
23
Dexetimide Withdrawn Phase 2, Phase 3 21888-98-2 30843
24
Nimotuzumab Investigational Phase 3 780758-10-3
25
Rindopepimut Investigational Phase 3 1108208-65-6
26
Semustine Experimental, Investigational Phase 3 13909-09-6 5198
27
GDC-0084 Investigational Phase 2, Phase 3 1382979-44-3 57384863
28
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
29
Dianhydrogalactitol Investigational Phase 3 23261-20-3
30
Trabedersen Investigational Phase 3 925681-61-4
31 interferons Phase 3
32 Interferon-alpha Phase 3
33
Imatinib Mesylate Phase 3 220127-57-1
34 Anesthetics Phase 3
35 Anticonvulsants Phase 3
36 Psychotropic Drugs Phase 3
37 Neurotransmitter Agents Phase 3
38 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
39
Etoposide phosphate Phase 3 16760419
40 Micronutrients Phase 3
41 Vitamins Phase 3
42 Trace Elements Phase 3
43 Pharmaceutical Solutions Phase 3
44 Protective Agents Phase 3
45 Antioxidants Phase 3
46 Analgesics Phase 3
47 Retinol palmitate Phase 3
48 Dopamine Agents Phase 3
49 Immunoconjugates Phase 3
50 Antidepressive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 1518)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 Pilot Study of Resection and GammaTile Followed by Concomitant External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant in Newly Diagnosed Glioblastoma (GBM) Recruiting NCT05342883 Phase 4
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM). Not yet recruiting NCT05235737 Phase 4 Pembrolizumab
5 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
6 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
7 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
8 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
9 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
10 Proteome-based Personalized Immunotherapy of Malignant Brain Tumors Unknown status NCT01759810 Phase 2, Phase 3
11 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
12 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
13 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
14 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
15 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
16 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
17 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
18 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
19 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
20 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
21 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
22 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
23 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
24 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
25 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
26 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
27 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
28 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
29 Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma Completed NCT01290939 Phase 3 lomustine
30 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
31 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
32 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Completed NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
33 A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498) Completed NCT02617589 Phase 3 Nivolumab;Temozolomide
34 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
35 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Lomustine Chemotherapy;Placebo Cediranib
36 A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) Completed NCT02573324 Phase 2, Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
37 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
38 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
39 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
40 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
41 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
42 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Completed NCT01805453 Phase 3 Losartan;Placebo
43 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
44 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
45 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
46 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
47 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
48 A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM) Recruiting NCT05271240 Phase 3 Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation;Temozolomide and Radiation Alone
49 A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study Recruiting NCT03025893 Phase 2, Phase 3 Sunitinib;Lomustine
50 A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) Recruiting NCT02685605 Phase 3 Temozolomide

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 28
2 Glioblastoma Multiforme 28

Anatomical Context for Glioblastoma

Organs/tissues related to Glioblastoma:

MalaCards : Brain, T Cells, Eye, Myeloid, Spinal Cord, Bone Marrow, Endothelial

Publications for Glioblastoma

Articles related to Glioblastoma:

(show top 50) (show all 33846)
# Title Authors PMID Year
1
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. 53 62 46
19773441 2009
2
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 53 62 46
18577219 2008
3
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. 53 62 46
17721077 2007
4
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
5
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. 62 46
20227367 2010
6
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. 62 46
19559015 2009
7
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. 62 46
19159078 2009
8
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). 62 46
18759060 2009
9
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. 62 46
19013014 2008
10
MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. 62 46
18765229 2008
11
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. 62 46
18829576 2008
12
Extensive modulation of a set of microRNAs in primary glioblastoma. 62 46
16039986 2005
13
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. 62 46
16024602 2005
14
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 53 62
19937796 2010
15
Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. 53 62
20177775 2010
16
miR-182 as a prognostic marker for glioma progression and patient survival. 46
20472885 2010
17
Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. 53 62
20514402 2010
18
New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. 53 62
20305620 2010
19
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. 53 62
20428822 2010
20
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. 53 62
20388502 2010
21
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. 53 62
20428809 2010
22
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. 53 62
20467331 2010
23
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. 53 62
20195615 2010
24
Amplicons on chromosome 12q13-21 in glioblastoma recurrences. 53 62
19839052 2010
25
Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. 53 62
20303140 2010
26
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. 53 62
19841865 2010
27
Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. 53 62
20302512 2010
28
Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines. 53 62
20162618 2010
29
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. 53 62
20309962 2010
30
FasL gene knock-down therapy enhances the antiglioma immune response. 53 62
20406899 2010
31
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. 53 62
20457619 2010
32
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. 53 62
20307616 2010
33
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. 53 62
19856144 2010
34
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. 53 62
19810093 2010
35
Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. 53 62
20199106 2010
36
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. 53 62
20372840 2010
37
Integrin alpha 6 regulates glioblastoma stem cells. 53 62
20452317 2010
38
The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. 53 62
19937366 2010
39
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. 53 62
20457618 2010
40
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. 53 62
20096265 2010
41
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. 53 62
20127344 2010
42
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. 53 62
20171141 2010
43
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. 53 62
20371721 2010
44
Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. 53 62
20298756 2010
45
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. 53 62
20436671 2010
46
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. 53 62
20308316 2010
47
Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. 53 62
20140015 2010
48
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. 53 62
20412570 2010
49
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. 53 62
20462843 2010
50
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. 53 62
20360941 2010

Variations for Glioblastoma

ClinVar genetic disease variations for Glioblastoma:

5 (show top 50) (show all 133)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 H3-3A NM_002107.7(H3-3A):c.103G>A (p.Gly35Arg) SNV Other
438766 rs1553260624 GRCh37: 1:226252155-226252155
GRCh38: 1:226064454-226064454
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp) SNV Other
438772 rs1556339256 GRCh37: X:70357729-70357729
GRCh38: X:71137879-71137879
3 BCOR NM_001123385.2(BCOR):c.3883_3884del (p.Leu1296fs) MICROSAT Other
284290 rs886042842 GRCh37: X:39922288-39922289
GRCh38: X:40063035-40063036
4 MSH2 NM_000251.3(MSH2):c.1958_1965del (p.Asn653fs) DEL Pathogenic
590849 rs1558518449 GRCh37: 2:47702360-47702367
GRCh38: 2:47475221-47475228
5 SLX4 NM_032444.4(SLX4):c.859_860del (p.Ser287fs) DEL Likely Pathogenic
620592 rs1567176006 GRCh37: 16:3652209-3652210
GRCh38: 16:3602208-3602209
6 DNMT3A NM_022552.5(DNMT3A):c.2710C>T (p.Pro904Ser) SNV Likely Pathogenic
635110 rs1558650888 GRCh37: 2:25457177-25457177
GRCh38: 2:25234308-25234308
7 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
8 MTOR NM_004958.4(MTOR):c.4448G>A (p.Cys1483Tyr) SNV Likely Pathogenic
Likely Pathogenic
376453 rs786205165 GRCh37: 1:11217230-11217230
GRCh38: 1:11157173-11157173
9 MTOR NM_004958.4(MTOR):c.4447T>C (p.Cys1483Arg) SNV Likely Pathogenic
374796 rs1057519914 GRCh37: 1:11217231-11217231
GRCh38: 1:11157174-11157174
10 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Likely Pathogenic
Likely Pathogenic
13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
11 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
12 ATM, C11orf65 NM_000051.4(ATM):c.8535G>A (p.Trp2845Ter) SNV Likely Pathogenic
555284 rs1555138291 GRCh37: 11:108216586-108216586
GRCh38: 11:108345859-108345859
13 PIK3CA NM_006218.4(PIK3CA):c.113G>A (p.Arg38His) SNV Likely Pathogenic
Likely Pathogenic
376492 rs772110575 GRCh37: 3:178916726-178916726
GRCh38: 3:179198938-179198938
14 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu) SNV Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
375899 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
15 CREBBP NM_004380.3(CREBBP):c.4336C>G (p.Arg1446Gly) SNV Likely Pathogenic
Likely Pathogenic
376388 rs398124146 GRCh37: 16:3788618-3788618
GRCh38: 16:3738617-3738617
16 PIK3CA NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala) SNV Likely Pathogenic
Likely Pathogenic
376499 rs1057519941 GRCh37: 3:178921549-178921549
GRCh38: 3:179203761-179203761
17 PIK3CA NM_006218.4(PIK3CA):c.1357G>C (p.Glu453Gln) SNV Likely Pathogenic
Likely Pathogenic
376471 rs1057519925 GRCh37: 3:178928079-178928079
GRCh38: 3:179210291-179210291
18 PIK3CA NM_006218.4(PIK3CA):c.333G>C (p.Lys111Asn) SNV Likely Pathogenic
376483 rs1057519934 GRCh37: 3:178916946-178916946
GRCh38: 3:179199158-179199158
19 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely Pathogenic
Likely Pathogenic
376488 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
20 PIK3CA NM_006218.4(PIK3CA):c.112C>G (p.Arg38Gly) SNV Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
376496 rs749415085 GRCh37: 3:178916725-178916725
GRCh38: 3:179198937-179198937
21 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Likely Pathogenic
Likely Pathogenic
13654 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
22 EGFR NM_005228.5(EGFR):c.866C>T (p.Ala289Val) SNV Likely Pathogenic
Likely Pathogenic
376209 rs149840192 GRCh37: 7:55221822-55221822
GRCh38: 7:55154129-55154129
23 MYCNOS, MYCN NM_005378.6(MYCN):c.131C>T (p.Pro44Leu) SNV Likely Pathogenic
376460 rs1057519919 GRCh37: 2:16082317-16082317
GRCh38: 2:15942195-15942195
24 FBXW7 NM_001349798.2(FBXW7):c.1435C>G (p.Arg479Gly) SNV Likely Pathogenic
376422 rs747241612 GRCh37: 4:153247367-153247367
GRCh38: 4:152326215-152326215
25 EGFR NM_005228.5(EGFR):c.322A>G (p.Arg108Gly) SNV Likely Pathogenic
376400 rs1057519888 GRCh37: 7:55211079-55211079
GRCh38: 7:55143386-55143386
26 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely Pathogenic
Likely Pathogenic
376487 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
27 EGFR NM_005228.5(EGFR):c.865_866delinsAA (p.Ala289Asn) INDEL Likely Pathogenic
Likely Pathogenic
376397 rs1057519887 GRCh37: 7:55221821-55221822
GRCh38: 7:55154128-55154129
28 IDH1 NM_005896.4(IDH1):c.395G>T (p.Arg132Leu) SNV Likely Pathogenic
Likely Pathogenic
375889 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
29 FBXW7 NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln) SNV Likely Pathogenic
376427 rs759610249 GRCh37: 4:153244184-153244184
GRCh38: 4:152323032-152323032
30 EGFR NM_005228.5(EGFR):c.2155G>T (p.Gly719Cys) SNV Likely Pathogenic
16611 rs28929495 GRCh37: 7:55241707-55241707
GRCh38: 7:55174014-55174014
31 PIK3CA NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His) SNV Likely Pathogenic
376490 rs1057519939 GRCh37: 3:178921551-178921551
GRCh38: 3:179203763-179203763
32 EGFR NM_005228.5(EGFR):c.2156G>A (p.Gly719Asp) SNV Likely Pathogenic
Likely Pathogenic
376075 rs121913428 GRCh37: 7:55241708-55241708
GRCh38: 7:55174015-55174015
33 PIK3R1 NM_181523.3(PIK3R1):c.1126G>C (p.Gly376Arg) SNV Likely Pathogenic
376065 rs1057519757 GRCh37: 5:67589138-67589138
GRCh38: 5:68293310-68293310
34 PIK3CA NM_006218.4(PIK3CA):c.1359A>T (p.Glu453Asp) SNV Likely Pathogenic
376472 rs1057519926 GRCh37: 3:178928081-178928081
GRCh38: 3:179210293-179210293
35 PIK3CA NM_006218.4(PIK3CA):c.331A>G (p.Lys111Glu) SNV Likely Pathogenic
376482 rs1057519933 GRCh37: 3:178916944-178916944
GRCh38: 3:179199156-179199156
36 FBXW7 NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln) SNV Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
376419 rs866987936 GRCh37: 4:153247366-153247366
GRCh38: 4:152326214-152326214
37 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely Pathogenic
376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
38 PIK3CA NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His) SNV Likely Pathogenic
376491 rs1057519940 GRCh37: 3:178936096-178936096
GRCh38: 3:179218308-179218308
39 IDH1 NM_005896.4(IDH1):c.394C>A (p.Arg132Ser) SNV Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
375893 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
40 EGFR NM_005228.5(EGFR):c.1793G>T (p.Gly598Val) SNV Likely Pathogenic
Likely Pathogenic
376210 rs139236063 GRCh37: 7:55233043-55233043
GRCh38: 7:55165350-55165350
41 H3-3A NM_002107.7(H3-3A):c.100G>C (p.Gly34Arg) SNV Likely Pathogenic
376434 rs1057519902 GRCh37: 1:226252152-226252152
GRCh38: 1:226064451-226064451
42 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg) SNV Likely Pathogenic
376484 rs1057519935 GRCh37: 3:178916945-178916945
GRCh38: 3:179199157-179199157
43 CREBBP NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu) SNV Likely Pathogenic
Likely Pathogenic
376386 rs1057519884 GRCh37: 16:3788617-3788617
GRCh38: 16:3738616-3738616
44 POLE NM_006231.4(POLE):c.1231G>T (p.Val411Leu) SNV Likely Pathogenic
376503 rs1057519945 GRCh37: 12:133250289-133250289
GRCh38: 12:132673703-132673703
45 EGFR NM_005228.5(EGFR):c.865G>A (p.Ala289Thr) SNV Likely Pathogenic
376395 rs769696078 GRCh37: 7:55221821-55221821
GRCh38: 7:55154128-55154128
46 FGFR1 NM_023110.3(FGFR1):c.1968G>C (p.Lys656Asn) SNV Likely Pathogenic
376428 rs1057519897 GRCh37: 8:38272306-38272306
GRCh38: 8:38414788-38414788
47 PIK3CA NM_006218.4(PIK3CA):c.1030G>A (p.Val344Met) SNV Likely Pathogenic
376498 rs1057519942 GRCh37: 3:178921548-178921548
GRCh38: 3:179203760-179203760
48 TP53 NM_000546.6(TP53):c.658T>A (p.Tyr220Asn) SNV Likely Pathogenic
Likely Pathogenic
Likely Pathogenic
376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
49 MTOR NM_004958.4(MTOR):c.6643T>A (p.Ser2215Thr) SNV Likely Pathogenic
376457 rs1057519917 GRCh37: 1:11184574-11184574
GRCh38: 1:11124517-11124517
50 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely Pathogenic
376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066

Copy number variations for Glioblastoma from CNVD:

6 (show top 50) (show all 797)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13758 1 1 28000000 Copy number Glioblastoma
10 13761 1 1 28000000 Deletion Glioblastoma multiforme
11 13763 1 1 28000000 Gain Glioblastoma multiforme
12 13775 1 1 39600000 Loss Glioblastoma multiforme
13 13792 1 1 51300000 Loss Glioblastoma multiforme
14 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
15 14314 1 107000000 111600000 Gain Glioblastoma multiforme
16 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
17 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
18 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
19 16435 1 124300000 247249719 Gain Glioblastoma multiforme
20 16436 1 124300000 247249719 Gain Glioblastoma multiforme
21 16437 1 124300000 247249719 Gain Glioblastoma multiforme
22 16444 1 124300000 247249719 Loss Glioblastoma multiforme
23 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
24 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
25 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
26 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
27 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
28 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
29 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
30 23682 1 172900000 185800000 Gain Glioblastoma multiforme
31 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
32 25428 1 189000000 197500000 Gain Glioblastoma multiforme
33 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
34 26137 1 197500000 205300000 Amplification LRRN2 Glioblastoma multiforme
35 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
37 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
38 26146 1 197500000 205300000 Amplificationlication MDM2 Glioblastoma multiforme
39 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
40 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
41 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
42 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
43 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
44 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
45 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
46 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
47 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
48 31747 1 30500000 171200000 Gain Glioblastoma multiforme
49 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
50 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme

Expression for Glioblastoma

Search GEO for disease gene expression data for Glioblastoma.

Pathways for Glioblastoma



Pathways directly related to Glioblastoma:

# Pathway Source
1 Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate Reactome 66

Pathways related to Glioblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.63 MIR222 MIR221 MIR21

GO Terms for Glioblastoma

Cellular components related to Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.8 MIR326 MIR296 MIR222 MIR221 MIR21 MIR17HG
2 extracellular vesicle GO:1903561 9.02 MIR451A MIR34A MIR222 MIR221 MIR21

Biological processes related to Glioblastoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.87 MIR451A MIR34A MIR21 MIR137
2 negative regulation of angiogenesis GO:0016525 9.78 MIR34A MIR222 MIR21 MIR137
3 negative regulation of protein kinase B signaling GO:0051898 9.73 MIR451A MIR34A MIR137
4 positive regulation of epithelial to mesenchymal transition GO:0010718 9.72 MIR222 MIR221 MIR21
5 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.7 MIR222 MIR221 MIR21
6 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.69 MIR34A MIR182 MIR137
7 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.62 MIR222 MIR221 MIR21 MIR182
8 positive regulation of axon regeneration GO:0048680 9.59 MIR222 MIR221
9 negative regulation of cell adhesion molecule production GO:0060354 9.58 MIR222 MIR221
10 negative regulation by host of viral genome replication GO:0044828 9.58 MIR222 MIR221
11 miRNA-mediated gene silencing GO:0035195 9.55 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
12 negative regulation of xenobiotic detoxification by transmembrane export across the plasma membrane GO:1905700 9.54 MIR451A MIR326
13 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.54 MIR451A MIR221 MIR21
14 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.49 MIR222 MIR221
15 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.46 MIR222 MIR221
16 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.46 MIR34A MIR21 MIR182 MIR137
17 positive regulation of Schwann cell migration GO:1900149 9.43 MIR221 MIR222
18 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR221 MIR222
19 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.26 MIR222 MIR221
20 negative regulation of interleukin-21 production GO:0032705 9.13 MIR222 MIR221 MIR21

Molecular functions related to Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR451A MIR34A MIR326 MIR296 MIR21 MIR137
2 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR451A MIR34A MIR326 MIR296 MIR222 MIR221

Sources for Glioblastoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....